#nebulization

Nebulized inhalation is a direct drug delivery method using the respiratory tract and lungs as the target organs, and has become a key means of treating respiratory-related diseases with its advantages of rapid onset of action, high local drug concentration, lower dosage, convenient application and fewer systemic adverse effects. However, unregulated use of nebulized inhalation therapy may not only directly impair the therapeutic effect, but also cause safety hazards, posing a threat to the life and health of patients.

Nebulized inhalation therapy uses a nebulized inhalation device to convert medication into aerosol particles with diameters ranging from 0.01 to 10 μm, which are inhaled and deposited in the airways and lungs to exert therapeutic effects. The diameter of the nebulized particles directly affects where the drug is deposited in the body, and effective nebulized particles should have a diameter between 0.5 and 10 μm. The effective nebulized particles should be between 0.5 and 10 μm in diameter. 5 to 10 μm diameter particles are mainly deposited in the oropharynx, 3 to less than 5 μm particles are mainly deposited in the lungs, and 50% to 60% of particles less than 3 μm are deposited in the alveoli.

In 2022, the world's first nebulized inhalation new crown vaccine was launched, breaking the traditional route of vaccine administration. Not only has it shown good safety and immunogenicity in clinical data, but it can also induce mucosal immunity, which has brought a breakthrough in the development of respiratory vaccines.

Meanwhile, the first nebulized inhalation antibiotic tobramycin inhalation solution for the treatment of bronchiectasis was listed on the market, which changed the status quo that no drug was available in China in the field of nebulized inhalation treatment for bronchiectasis patients, providing more support for bronchiectasis patients and improving their quality of life.

Nebulized Inhalation Therapy: An Innovative Way to Expand the Field of Treatment

Nebulized inhalation therapy (NIT) is a method of drug delivery in which drugs are atomized by a special drug delivery device and inhaled into the lungs by the patient in the form of an aerosol to exert a local or systemic effect for preventive, therapeutic or diagnostic purposes. It is the preferred method of drug delivery for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and can also be used for the treatment of pulmonary fibrosis, lung cancer and other respiratory diseases.

With the continuous development of nebulized medicine, nebulized therapy is no longer limited to the classic nebulized drugs such as budesonide and salbutamol, but scientists are now doing more research in new areas, and nebulized inhalation therapy has been shown to be an alternative to injectable routes of administration of peptides and proteins in situations such as systemic administration of medications, gene therapy, or vaccine administration. The above mentioned drugs that have been on the market for a short period of time are good examples of this.

More details on the website: www.feelife.com.

Abstract：Nebulizers, crucial devices in respiratory care, transform liquid medication into an inhalable mist, primarily used to address respiratory conditions like asthma, COPD, and pulmonary hypertension. In the ICU, nebulizers play a vital role in delivering bronchodilators and anti-inflammatory agents, with potential applications in treating hemoptysis.

A nebulizer is a device that turns liquid medication into a tiny mist that may be inhaled into the lungs. Nebulizers are often used to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), or pulmonary hypertension. Nebulizers can also be used to deliver other medications, such as antibiotics, antifungals, or hemostatic agents .

Abstract

Aim: Salbutamol is the main treatment for asthma attacks. It can be given via inhaler, nebulizer or oral route. Nebulization is mainly used at emergency departments. The aim of our study is to compare the clinical efficacy of two nebulized salbutamol preparations Ventolin® GSK and Asthalin® CIPLA.

Methods: We conducted a prospective double blind randomized trial between April and December 2017 in which 30 children with asthma were included. Children were assigned randomly to receive nebulized Asthalin® or Ventolin®, with 15 patients included in each study arm. For each patient, oxygen saturation, presence of wheezing, retractions and thoraco-abdominal asynchrony, before and after Salbutamol nebulization were recorded. The effect of each treatment dose on oxygen saturation and respiratory rate after stratification of the initial population was analyzed.

Results: Ventolin® increased oxygen saturation by 1.87% and decreased respiratory rate by 10.87 breaths per minute, while Asthalin® improved oxygen saturation by 1.8% and decreased respiratory rate by 9.53 breaths per minute. However, the difference was not significant as it was not significant for respiratory symptoms improvement and need for oxygenation and hospitalization rates.

Conclusion: There is no significant difference between Ventolin® and Asthalin® when given via nebulization. Both treatments improved oxygen saturation, respiratory rate and respiratory symptoms similarly.

To read more 

A nebulizer is a device that is used to provide the medication directly and quickly to the lungs of a person with severe respiratory conditions like asthma.

Nebulization at Home, Exclusively for Seniors